With 0.78 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.91 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7 whereas the lowest price it dropped to was $0.5725. The 52-week range on XRTX shows that it touched its highest point at $1.79 and its lowest point at $0.60 during that stretch. It currently has a 1-year price target of $14.00. Beta for the stock currently stands at 0.23.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XRTX was down-trending over the past week, with a drop of -3.55%, but this was down by -20.13% over a month. Three-month performance dropped to -15.92% while six-month performance fell -38.85%. The stock lost -43.43% in the past year, while it has lost -56.82% so far this year. A look at the trailing 12-month EPS for XRTX yields -0.54 with Next year EPS estimates of -0.35. For the next quarter, that number is -0.17. This implies an EPS growth rate of 39.98% for this year and 49.29% for next year.
Float and Shares Shorts:
At present, 5.78 million XRTX shares are outstanding with a float of 4.61 million shares on hand for trading. On 2025-10-15, short shares totaled 7330.0, which was 13.999999999999998 higher than short shares on 1757894400. In addition to Dr. Allen Warren Davidoff Ph.D. as the firm’s Founder, CEO, President & Director, Dr. Michael Scott Bumby D.V.M., M.B.A. serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.046430003 of XRTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, XRTX reported revenue of $0.0 and operating income of -$889945.0. The EBITDA in the recently reported quarter was -$1022234.0 and diluted EPS was -$0.19.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With XRTX analysts setting a high price target of 13.694053 and a low target of 13.694053, the average target price over the next 12 months is 13.694053. Based on these targets, XRTX could surge 2039.7% to reach the target high and rise by 2039.7% to reach the target low. Reaching the average price target will result in a growth of 2039.7% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.15714 being high and -$2.15714 being low. For XRTX, this leads to a yearly average estimate of -$2.15714.
